Future-Proofing Your USP <87> Strategy: Preparing for the Next Generation of Biological Reactivity Testing

As the December 1, 2026 release of the revised USP <87>, Biological Reactivity Tests, In Vitro, approaches, pharmaceutical and medical device manufacturers should begin evaluating how these changes may impact their material qualification, biological evaluation, and compliance strategies. While the final chapter has not yet been published, the proposed direction reflects a broader industry shift toward modern, science-based in vitro testing approaches, quantitative data generation, and risk-based assessment methodologies.

Join Pace® Life Sciences for an informative webinar exploring what organizations can expect from the upcoming revisions, how evolving regulatory expectations may influence testing programs, and practical steps to prepare before implementation. Our scientific experts will discuss anticipated changes, the potential impact on qualification and validation activities, and how proactive planning can help ensure a smooth transition while maintaining compliance and operational efficiency.

Key learning objectives:

• Understand the anticipated revisions to USP <87> and how they reflect the industry’s shift toward modern, science-based in vitro biological reactivity testing
• Evaluate the potential impact on your organization by exploring how the revised chapter may affect material qualification, biological evaluation strategies, validation activities, and regulatory documentation
• Learn practical steps to prepare for implementation by developing a proactive strategy for testing readiness, laboratory planning, and compliance before the revised chapter is released